Literature DB >> 12849799

Ortho Evra/Evra versus oral contraceptives: follicular development and ovulation in normal cycles and after an intentional dosing error.

Roger A Pierson1, David F Archer, Michèle Moreau, Gary A Shangold, Alan C Fisher, George W Creasy.   

Abstract

OBJECTIVE: To compare the effects of the contraceptive patch to oral contraceptives (OCs) on follicular size and incidence of ovulation in normal cycles and after dosing errors.
DESIGN: Randomized, open-label.
SETTING: Twelve centers. PATIENT(S): One hundred twenty-four ovulatory women. INTERVENTION(S): Subjects received either the patch (groups 1 and 2) or one of three OCs. Correct dosing occurred in cycles 1, 2, 3, and 5. The following dosing errors were planned during cycle 4, a shortened 10-day cycle: [1] patch group 1 subjects wore one patch for 10 consecutive days; [2] for patch group 2 and OC subjects, 7 dosing days were followed by 3 drug-free days. MAIN OUTCOME MEASURE(S): Follicular size, as determined at each cycle by the maximum mean follicular diameter. RESULT(S): After a 3-day dosing error, follicular size was significantly smaller in the patch group (mean, 7.0 mm) vs. each OC group (range of means, 11.8-17.1 mm). Similar results were seen after proper dosing. The incidence of ovulation was significantly lower for the patch users than for women using OCs. CONCLUSION(S): Follicular size and incidence of ovulation were significantly reduced among contraceptive patch users compared with women using OCs in normal cycles and after planned dosing errors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12849799     DOI: 10.1016/s0015-0282(03)00556-9

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  9 in total

Review 1.  Mechanism of action of levonorgestrel emergency contraception.

Authors:  Chris Kahlenborn; Rebecca Peck; Walter B Severs
Journal:  Linacre Q       Date:  2015-02

Review 2.  Effect of missed combined hormonal contraceptives on contraceptive effectiveness: a systematic review.

Authors:  Lauren B Zapata; Maria W Steenland; Dalia Brahmi; Polly A Marchbanks; Kathryn M Curtis
Journal:  Contraception       Date:  2012-10-22       Impact factor: 3.375

Review 3.  Ovarian follicular development during the use of oral contraception: a review.

Authors:  Angela R Baerwald; Roger A Pierson
Journal:  J Obstet Gynaecol Can       Date:  2004-01

Review 4.  Skin patch and vaginal ring versus combined oral contraceptives for contraception.

Authors:  Laureen M Lopez; David A Grimes; Maria F Gallo; Laurie L Stockton; Kenneth F Schulz
Journal:  Cochrane Database Syst Rev       Date:  2013-04-30

5.  Systematic Review of Ovarian Activity and Potential for Embryo Formation and Loss during the Use of Hormonal Contraception.

Authors:  Donna Harrison; Cara Buskmiller; Monique Chireau; Lester A Ruppersberger; Patrick P Yeung
Journal:  Linacre Q       Date:  2019-01-03

6.  Ultrasound image attributes of human ovarian dominant follicles during natural and oral contraceptive cycles.

Authors:  Rebecca L Birtch; Angela R Baerwald; Olufemi A Olatunbosun; Roger A Pierson
Journal:  Reprod Biol Endocrinol       Date:  2005-04-13       Impact factor: 5.211

7.  Satisfaction and compliance in hormonal contraception: the result of a multicentre clinical study on women's experience with the ethinylestradiol/norelgestromin contraceptive patch in Italy.

Authors:  Pier Giorgio Crosignani; Carmine Nappi; Salvatore Ronsini; Vincenzina Bruni; Silvia Marelli; Davide Sonnino
Journal:  BMC Womens Health       Date:  2009-06-30       Impact factor: 2.809

8.  Safety, efficacy and patient acceptability of the combined estrogen and progestin transdermal contraceptive patch: a review.

Authors:  Alessandra Graziottin
Journal:  Patient Prefer Adherence       Date:  2008-02-02       Impact factor: 2.711

9.  Mathematical modeling of the release of active ingredients from a contraceptive patch: ortho evra(®) as a case study.

Authors:  Grissel Trujillo-de Santiago; Carlos Patricio Sáenz-Collins; Lizette García-Arellano; Mario Moisés Álvarez
Journal:  Iran J Pharm Res       Date:  2014       Impact factor: 1.696

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.